Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- Iressa Cases Signal Risks Hiding in Daily Clinical Practices
April 22, 2013
- Will Drugs that Fight Cancer Stem Cells Succeed? Domestic Clinical Trial by DSP on the Horizon
March 15, 2013
- Gov’t, Industry to Support Developing Countries through Development of Drugs for Infectious Diseases; Hoping to Secure Future Business Opportunities as Well
February 27, 2013
- What Next for a “Mature” ICH? What More Can Be Done Beyond Regulatory Harmonization?
January 22, 2013
- Hot Products in 2013: New Drugs Likely to Jolt RA Treatment, Anticoagulant Markets
January 8, 2013
- Counterfeit Drugs: Risks Lurking in Globalization
December 28, 2012
- Can Japan Craft Its Own “Compassionate Use” System without Spoiling Drug Makers’ Development Drives?
December 7, 2012
- Recent Announcements of Suspended Product Supplies Highlight Supply Risks Faced by Generic Drug Industry
November 27, 2012
- Will Integration of Domestic Makers Be Enough for Sustainable Plasma Fractionation Operations?
November 16, 2012
- Approval of Switch-OTC Epadel Puts Spotlight on Quality, Track Record of Pharmacists
November 9, 2012
- Final Preparations Underway for Trial Run of Medical Database
September 25, 2012
- Competition Getting Fiercer in COPD Drug Market
September 13, 2012
- FY2013 Budget Expected to Have Positive Impact on Pharmaceutical and Medical Device Industries
August 30, 2012
- Pharmaceutical Bar Coding Initiatives Spreading Among Western Countries
August 21, 2012
- Government Shows Consideration towards Municipalities on IPV Price Issue
August 14, 2012
- Challenges Emerging from Hiroshima: Improvement of Wholesalers' “Services of Convenience”
August 1, 2012
- Integration of Advanced Healthcare System to Strengthen Linkage Between Development, Insurance, and Regulatory Approval
July 10, 2012
- Major Generic Drug Makers Trying New Strategies to Boost Product Strengths
July 6, 2012
- Gov’t to Support Development of Innovative Drugs of Japanese Origin through Drug Discovery Support Network
June 22, 2012
- Discussions on Long-Listed Drugs Must Balance Interests of All Stakeholders
June 14, 2012
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…